Recent public disclosures highlight DSwiss's strategic collaboration with RECOMM Co Ltd for a COVID-19 sterilizer and purifier product and the launch of a new DNA testing business. The company continues to expand its market presence and product offerings in the health and beauty sectors.

• DSwiss announced a strategic collaboration with Japan-listed RECOMM Co Ltd for a COVID-19 Killer air and surface sterilizer and purifier [N1].
• The company announced a new DNA testing business in September 2020 [N2].
• DSwiss reported net income of $4,291 and basic and diluted EPS of $0.0001 for the quarter ended March 31, 2026, with cash and equivalents of $220,027 [S2].
• The company is actively expanding its marketing efforts through social media campaigns and e-commerce platforms to increase product visibility and brand awareness [S1].
• DSwiss is pursuing strategic mergers and acquisitions in healthcare, biotechnology, beauty, wellness, and food science sectors to complement organic growth [S1].

DSwiss Inc benefits from a diversified product portfolio spanning functional foods, skincare, personal care, pet wellness, and meal replacements, addressing growing consumer demand for health and beauty solutions. Its turnkey OEM/ODM model offers clients end-to-end services, including formulation, manufacturing, packaging, and regulatory support, which can attract and retain customers seeking comprehensive solutions. The company's strategic collaborations, such as with RECOMM Co Ltd for COVID-19 sterilization products, and expansion into DNA testing demonstrate adaptability and innovation. Its expanding workforce and marketing initiatives, including social media campaigns and international trade show participation, support market penetration and brand recognition.

DSwiss Inc faces challenges including liquidity constraints indicated by a current ratio below 1.0 and cash ratio under 0.5 as of March 31, 2026, which may limit operational flexibility. The company operates in highly competitive health and beauty markets with evolving consumer preferences and regulatory environments, which could impact product acceptance and compliance costs. Its relatively modest reported revenue and net income figures suggest limited scale. Dependence on OEM/ODM client relationships and the need to continuously innovate and expand market presence pose execution risks. Additionally, the company is a smaller reporting entity with limited disclosure of risk factors, which may obscure potential vulnerabilities.

DSwiss Inc's moat is built on its comprehensive turnkey OEM/ODM capabilities in the nutraceutical and beauty sectors, supported by stringent quality control and regulatory compliance across multiple jurisdictions. Its vertically integrated operations from R&D to manufacturing and packaging, combined with a diversified product portfolio and strong distributor network in Asia-Pacific, provide competitive advantages. The company's commitment to innovation, evidenced by its in-house R&D team and strategic collaborations, further strengthens its position. Additionally, its adherence to multiple certifications (GMP, HACCP, Halal, ISO) and ability to customize products for clients enhance customer loyalty and barriers to entry for competitors.

• Liquidity Risk: As of March 31, 2026, DSwiss reported a current ratio of 0.77 and cash ratio of 0.47, indicating current liabilities exceed current assets, which may constrain operational liquidity and financial flexibility.
• Market Competition and Regulatory Compliance: The health and beauty industry is highly competitive and subject to evolving regulations. Maintaining compliance with multiple standards (GMP, HACCP, Halal, ISO) requires ongoing investment and operational discipline.
• Execution Risk in Growth Initiatives: DSwiss is pursuing expansion through workforce growth, marketing campaigns, and mergers and acquisitions. Execution challenges in these areas could impact growth and profitability.
• Dependence on OEM/ODM Client Relationships: The company's business model relies on maintaining strong relationships with OEM/ODM clients. Loss of key clients or failure to attract new ones could adversely affect revenue.

• DSwiss Inc is a Nevada corporation incorporated on May 28, 2015, operating through wholly-owned subsidiaries including DSwiss Holding Limited (Seychelles), DSwiss (HK) Limited (Hong Kong), and DSwiss Sdn Bhd (Malaysia) [S1].
• The company is primarily engaged in supplying high-quality health and beauty products including weight management beverages, anti-aging solutions, and immune system enhancers [S1].
• DSwiss is a biotech nutraceutical firm and turnkey Private Label ODM/OEM provider specializing in premium healthcare, skincare, and personal care solutions [S1].
• The company offers a diverse product portfolio including functional foods, health supplements, skincare, personal care, pet wellness products, and meal replacement/complete nutrition products [S1].
• DSwiss operates production facilities adhering to GMP, HACCP, JAKIM Halal, ISO, and MESTI standards, ensuring quality and regulatory compliance [S1].
• The company provides end-to-end OEM/ODM services including custom formulation R&D, manufacturing, packaging, shipping, import/export, and regulatory licensing [S1].
• DSwiss has expanded its workforce with industry professionals in nutrition, science, laboratory, customer relations, and operations to support product development and innovation [S1].
• The company is actively expanding its market presence locally and internationally, enhancing marketing efforts through social media campaigns and e-commerce platforms [S1].
• DSwiss has strategic collaborations such as with Japan-listed RECOMM Co Ltd for a COVID-19 air and surface sterilizer and purifier [N1].
• The company announced a new DNA testing business in 2020 [N2].
• As of March 31, 2026, the company reported cash and equivalents of $220,027, current assets of $361,617, current liabilities of $471,855, a current ratio of 0.77, and a cash ratio of 0.47 [S2].
• For the quarter ended March 31, 2026, DSwiss reported net income of $4,291 and basic and diluted EPS of $0.0001 [S2].
• Revenue reported for the quarter ended September 30, 2024, was $2,125 [S2].
• The company generated $2,920,986 revenue for the year ended December 31, 2025, mainly from OEM/ODM sales of nutraceutical, skincare, and medical consumable supplies [S1].
• DSwiss is pursuing strategic mergers and acquisitions in healthcare, biotechnology, beauty, slimming, wellness, and food science sectors to complement organic growth [S1].
• The company owns trademarks registered in multiple jurisdictions including Cambodia, Malaysia, Singapore, China, Hong Kong, India, Myanmar, Vietnam, and the EUIPO [S1].
• DSwiss emphasizes innovation, quality control, and regulatory compliance in product development, sourcing premium natural ingredients and conducting rigorous testing [S1].
• The company offers expert consultancy and strategic marketing solutions to clients to support business growth and market competitiveness [S1].